Lipiodol Ultra-Fluide Dosage/Direction for Use

In diagnostic radiology: Lymphography: Admister via a catheter inserted into a lymph duct. A dye can first be injected to locate the lymph ducts.
The usual dose is 5 to 7 mL via the strict lymphatic route to enhance contrast in an extremity (depending on the height of the subject), i.e. 10 to 14 mL for bilateral lymphography of the feet.
Hysterosalpingography: Adminstration is by slow injection into the uterine cervical canal via a syringe and suitable cannula.
The recommended dose is 10 to 20 mL, depending on the volume of the uterine cavity.
Sialography: Administration is by cannulation of salivary duct. Not more than 5 mL until the salivary gland is filled.
Paediatric Population: The dose must be reduced proportionally in children. In infants 1 to 2 years of age, a dose of 1 mL per extremity is sufficient.
Patients with low weight: The dose must be reduced proportionally in this population.
Elderly: The product must be administered with special care in patients over 65 years of age with underlying diseases of the cardiovascular, respiratory or nervous systems. Keeping in mind that part of the product temporarily embolises the pulmonary capillaries, the dose must be adjusted in elderly patients with cardio-respiratory failure or the examination must be cancelled.
In Interventional Radiology: Trans-Arterial Chemo-Embolisation of hepatocellular carcinoma: The administration is by selective intra-arterial catheterism of the hepatic artery. The procedure should be performed within a typical interventional radiology setting with the apporpriate equipment. The dose of LIPIODOL ULTRA-FLUIDE can be mixed with anticancer drugs such as cisplatin, doxorubicin, epirubicin and mitomycin. Instructions and precatuions for use of the anticancer drugs must be strictly followed.
Instructions for preparation of the mixture of LIPIODOL ULTRA-FLUIDE with an anticancer drug: Prepare two syringes large enough to contain the total volume of mixture. The first syringe contains the anticancer drug solution, the second syringe contains LIPIODOL ULTRA-FLUIDE.
Connect the two syringes to a 3-way stopcock.
Perform 15 to 20 back and forth movements between the two syringes to obtain a homogenous mixture. It is recommended to start by pushing the syringe with the anticancer drug first.
The mixture is to be prepared at the time of use and must be used promptly after preparation (within 3 hours). If necessary during the interventional radiology procedure, the mixture can be re-homogenised as describes from the previous text.
When the adequate mixture is obtained, use a 1 to 3 mL syringe to inject in the micro-catheter.
The procedure can be repeated every 4 to 8 weeks according to tumour response and patient conditions.
Paediatric population: The efficacy and safety of the use of LIPIODOL ULTRA-FLUIDE for Trans-Arterial Chemo-Embolisation of hepatocellular carcinoma have not been established in children.
Elderly: The product must be administered with special care in patients over 65 years of age with underlying disease of cardiovascular, respiratory or nervous systems.